Cyclophosphamide Treatment Options

A collection of 2172 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170

Withdrawn

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2021

Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California

Conditions: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent

Learn More ›

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

NCT02243371

Completed

The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2021

Locations: University of California, San Francisco, San Francisco, California +4 locations

Conditions: Previously Treated Metastatic Adenocarcinoma of the Pancreas

Learn More ›

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411

Terminated

This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.

Gender:

ALL

Ages:

44 years and below

Trial Updated:

03/17/2021

Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

NCT01045460

Completed

Patient Population: Patients with active myeloma (Stage II/III) that have completed induction therapy and are eligible for an autologous stem cell transplant. Number of Patients: Will treat a total of 32 evaluable patients in a 1:1 randomization of aMILs vs aMILs plus vaccine. An evaluable patient is defined as one which has received the activated MILs and is at least 6 months post-transplant. Study Objectives: Disease response as determined by the Blade' criteria will be the primary endpoint... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

03/16/2021

Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Conditions: Multiple Myeloma

Learn More ›

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

NCT01338987

Completed

Background: * One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients. One problem with these transplants is that the new immune cells may not work as well in the recipient as they did in the donor. The result may be that the immune system will not work as well. This can increase the risk of severe infections and other complications. * Researchers are studying the use of drugs that lower hormone levels and may allow the immune system to recover in a way that improves white blood cell function. In this study they will be looking at the drug leuprolide, a drug that lowers estrogen or testosterone levels, to see if it might improve the function of the newly transplanted cells. Objectives: * To determine whether leuprolide improves immune system function after bone marrow transplant from a donor with similarities in their immune cells (matched to each other). * To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug 3-deoxy-3 18F-fluorothymidine (FLT) in imaging studies. FLT will be used to image the immune system function in patients who have received bone marrow from the donor. Eligibility: * People between 15 (or as young as 9 in those who have gone through puberty) and 55 years of age. These patients must have acute myelogenous leukemia, acute lymphocytic leukemia, high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or chronic myeloid leukemia. They must also be eligible for a bone marrow transplant. * Genetically similar donors for the patients who are eligible for a transplant. Design: * People taking part in the study will be screened with a physical examination, medical history, blood and urine tests, and imaging studies. Patients who are not in remission or who require a bone marrow donor search may receive chemotherapy first. * Donors will provide bone marrow for transplant according to standard bone marrow transplant (BMT) procedures. * All women and half of the men will receive regular leuprolide doses 2 weeks before BMT to suppress hormone function. * All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy before the bone marrow transplant (depending on age). Recipients will also receive other drugs to prevent transplant rejection and other complications of transplantation. * Recipients will be monitored in the hospital for 4 weeks after transplant with blood tests and other studies. * Some recipients will have an imaging study with FLT during the protocol. These imaging studies will take place before the transplant, on days 5 and 28 after transplant, and at a later time to be determined by the study researchers. * Following discharge, participants will be monitored closely for up to 6 months, with regular but less frequent followup visits for at least 5 years. Study-related medications, including vaccinations for the new immune system, will be provided by the National Institutes of Health during the hospital stay and after discharge. Read Less

Gender:

ALL

Ages:

Between 4 years and 55 years

Trial Updated:

03/16/2021

Locations: Childrens National Medical Center, Washington, District of Columbia +2 locations

Conditions: Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia

Learn More ›

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

NCT01967823

Completed

Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying them, and then giving the cells back to the patient. In a previous study the NCI Surgery Branch used the anti-ESO-1 gene and a type of virus (retrovirus) to make these tumor fighting cells (anti-ESO-1 cells). About half of the patients who received this treatment experienced shrinking of their tumors. In this study, we are using a slightly different method of producing the anti-ESO-1 cells which we hope will be better in making the tumors shrink. Objectives: The purpose of this study is to see if these tumor fighting cells (genetically modified cells) that express the receptor for the ESO-1 molecule on their surface can cause tumors to shrink and to see if this treatment is safe. Eligibility: - Patients 15 years old and older with cancer that has the ESO-1 molecule on their tumors. Design: * Work up stage: Patients will be seen as an outpatient at the National Institutes of Health (NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed * Leukapheresis: If the patients meet all of the requirements for the study they will undergo leukapheresis to obtain white blood cells to make the anti ESO-1 cells. {Leukapheresis is a common procedure which removes only the white blood cells from the patient.} * Treatment: Once their cells have grown the patients will be admitted to the hospital for the conditioning chemotherapy, the anti-ESO-1 cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. * Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits take up to 2 days. Read Less

Gender:

ALL

Ages:

Between 15 years and 70 years

Trial Updated:

03/01/2021

Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland

Conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer

Learn More ›

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

NCT00002611

Completed

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney canc... Read More

Gender:

ALL

Ages:

Between 0 years and 15 years

Trial Updated:

02/23/2021

Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +234 locations

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

University of South Alabama Medical Center, Mobile, Alabama

Phoenix Children's Hospital, Phoenix, Arizona

Arizona Cancer Center, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Southern California Permanente Medical Group, Downey, California

City of Hope Comprehensive Cancer Center, Duarte, California

Rebecca and John Moores UCSD Cancer Center, La Jolla, California

Loma Linda University Medical Center, Loma Linda, California

Jonathan Jaques Children's Cancer Center, Long Beach, California

Children's Hospital Los Angeles, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Children's Hospital Central California, Madera, California

Children's Hospital of Oakland, Oakland, California

Chao Family Comprehensive Cancer Center, Orange, California

Children's Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital at Stanford, Palo Alto, California

Sutter Cancer Center, Sacramento, California

University of California Davis Medical Center, Sacramento, California

Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California

Children's Hospital San Diego, San Diego, California

Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California

UCSF Comprehensive Cancer Center, San Francisco, California

Santa Barbara Cottage Hospital, Santa Barbara, California

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California

David Grant Medical Center, Travis Air Force Base, California

Children's Hospital of Denver, Denver, Colorado

Childhood Hematology/Oncology Associates, Denver, Colorado

Presbyterian-St Luke's Medical Center, Denver, Colorado

University of Connecticut Health Center, Farmington, Connecticut

Yale Comprehensive Cancer Center, New Haven, Connecticut

Alfred I. Dupont Institute, Wilmington, Delaware

Lombardi Cancer Center, Washington, District of Columbia

Children's National Medical Center, Washington, District of Columbia

Walter Reed Army Medical Center, Washington, District of Columbia

Broward General Medical Center, Fort Lauderdale, Florida

Children's Hospital of Southwest Florida, Fort Myers, Florida

Shands Hospital and Clinics, University of Florida, Gainesville, Florida

Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida

Nemours Children's Clinic, Jacksonville, Florida

University of Miami-Jackson Memorial Hospital, Miami, Florida

Miami Children's Hospital, Miami, Florida

Baptist Hospital of Miami, Miami, Florida

Florida Hospital Cancer Institute, Orlando, Florida

Nemours Children's Clinic-Orlando, Orlando, Florida

Sacred Heart Children's Hospital, Pensacola, Florida

All Children's Hospital, Saint Petersburg, Florida

Tampa Children's Hospital, Tampa, Florida

St. Mary's Hospital, West Palm Beach, Florida

Emory University Hospital - Atlanta, Atlanta, Georgia

Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia

Medical College of Georgia Comprehensive Cancer Center, Augusta, Georgia

Medical Center of Central Georgia, Macon, Georgia

Memorial Health University Medical Center, Inc., Savannah, Georgia

Cancer Research Center of Hawaii, Honolulu, Hawaii

MBCCOP - Hawaii, Honolulu, Hawaii

Tripler Army Medical Center, Honolulu, Hawaii

Mountain States Tumor Institute, Boise, Idaho

University of Chicago Cancer Research Center, Chicago, Illinois

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

University of Illinois at Chicago, Chicago, Illinois

Children's Memorial Hospital - Chicago, Chicago, Illinois

Hope Children's Hospital, Oak Lawn, Illinois

Lutheran General Hospital, Park Ridge, Illinois

Saint Jude Midwest Affiliate, Peoria, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Indiana University Cancer Center, Indianapolis, Indiana

St. Vincent Hospital and Health Care Center, Indianapolis, Indiana

Raymond Blank Memorial Hospital for Children, Des Moines, Iowa

John Stoddard Cancer Center, Des Moines, Iowa

Holden Comprehensive Cancer Center, Iowa City, Iowa

Wesley Medical Center, Wichita, Kansas

Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky

Kosair Children's Hospital, Louisville, Kentucky

Tulane University School of Medicine, New Orleans, Louisiana

Children's Hospital of New Orleans, New Orleans, Louisiana

Ochsner Clinic, New Orleans, Louisiana

Eastern Maine Medical Center, Bangor, Maine

Maine Children's Cancer Program, Scarborough, Maine

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland

Sinai Hospital of Baltimore, Baltimore, Maryland

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Floating Hospital for Children, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Baystate Medical Center, Springfield, Massachusetts

University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts

Mott Children's Hospital, Ann Arbor, Michigan

Children's Hospital of Michigan, Detroit, Michigan

Henry Ford Hospital, Detroit, Michigan

St. John Hospital and Medical Center, Detroit, Michigan

Michigan State University, East Lansing, Michigan

Hurley Medical Center, Flint, Michigan

Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

CCOP - Beaumont, Royal Oak, Michigan

William Beaumont Hospital, Royal Oak, Michigan

St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota

Children's Hospitals and Clinics - Minneapolis, Minneapolis, Minnesota

Mayo Clinic Cancer Center, Rochester, Minnesota

Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Children's Mercy Hospital, Kansas City, Missouri

Cardinal Glennon Children's Hospital, Saint Louis, Missouri

St. Louis Children's Hospital, Saint Louis, Missouri

Children's Hospital of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Sunrise Hospital and Medical Center, Las Vegas, Nevada

Norris Cotton Cancer Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Cancer Institute of New Jersey, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

St. Joseph's Hospital and Medical Center, Paterson, New Jersey

Atlantic Health System, Summit, New Jersey

University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico

Cancer Center of Albany Medical Center, Albany, New York

Albert Einstein Clinical Cancer Center, Bronx, New York

Brooklyn Hospital Center, Brooklyn, New York

State University of New York Health Science Center at Brooklyn College of Medicine, Brooklyn, New York

Brookdale University Hospital and Medical Center, Brooklyn, New York

Maimonides Medical Center, Brooklyn, New York

Roswell Park Cancer Institute, Buffalo, New York

North Shore University Hospital, Manhasset, New York

Schneider Children's Hospital, New Hyde Park, New York

New York Presbyterian Hospital - Cornell Campus, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Mount Sinai School of Medicine, New York, New York

Columbia Presbyterian Hospital, New York, New York

James P. Wilmot Cancer Center, Rochester, New York

State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York

State University of New York - Upstate Medical University, Syracuse, New York

New York Medical College, Valhalla, New York

Mission Saint Joseph's Health System, Asheville, North Carolina

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina

Carolinas Medical Center, Charlotte, North Carolina

Presbyterian Healthcare, Charlotte, North Carolina

Duke Comprehensive Cancer Center, Durham, North Carolina

East Carolina University School of Medicine, Greenville, North Carolina

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina

Dakota Cancer Institute, Fargo, North Dakota

Children's Hospital Medical Center of Akron, Akron, Ohio

Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio

Ireland Cancer Center, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Children's Hospital of Columbus, Columbus, Ohio

Children's Medical Center - Dayton, Dayton, Ohio

Toledo Children's Hospital, Toledo, Ohio

St. Vincent Mercy Medical Center, Toledo, Ohio

Forum Health-Tod Childrens Hospital, Youngstown, Ohio

Children's Hospital of Oklahoma, Oklahoma City, Oklahoma

CCOP - Oklahoma, Tulsa, Oklahoma

Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma

Doernbecher Children's Hospital, Portland, Oregon

Legacy Emanuel Hospital and Health Center, Portland, Oregon

Geisinger Medical Center, Danville, Pennsylvania

Milton S. Hershey Medical Center, Hershey, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

Palmetto Health South Carolina Cancer Center, Columbia, South Carolina

Children's Hospital of Greenville Hospital System, Greenville, South Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

Sioux Valley Hospital, Sioux Falls, South Dakota

East Tennessee State University Cancer Center at JCMC, Johnson City, Tennessee

East Tennessee Children's Hospital, Knoxville, Tennessee

Saint Jude Children's Research Hospital, Memphis, Tennessee

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas

Children's Hospital of Austin, Austin, Texas

Medical City Dallas Hospital, Dallas, Texas

Simmons Cancer Center - Dallas, Dallas, Texas

Cook Children's Medical Center - Fort Worth, Fort Worth, Texas

University of Texas Medical Branch, Galveston, Texas

University of Texas - MD Anderson Cancer Center, Houston, Texas

Baylor College of Medicine, Houston, Texas

San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas

Covenant Children's Hospital, Lubbock, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Methodist Health Care System, San Antonio, Texas

Scott and White Memorial Hospital, Temple, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Vermont Cancer Center, Burlington, Vermont

Cancer Center at the University of Virginia, Charlottesville, Virginia

Inova Fairfax Hospital, Falls Church, Virginia

Children's Hospital of the King's Daughters, Norfolk, Virginia

Naval Medical Center, Portsmouth, Portsmouth, Virginia

Massey Cancer Center, Richmond, Virginia

Carilion Medical Center for Children, Roanoke, Virginia

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington

Fred Hutchinson Cancer Research Center, Seattle, Washington

Group Health Cooperative, Seattle, Washington

Deaconess Medical Center, Spokane, Washington

Mary Bridge Children's Health Center, Tacoma, Washington

Madigan Army Medical Center, Tacoma, Washington

West Virginia University - Charleston, Charleston, West Virginia

Cabell-Huntington Hospital, Inc, Huntington, West Virginia

West Virginia University Hospitals, Morgantown, West Virginia

Bellin Memorial Hospital, Green Bay, Wisconsin

CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin

St. Vincent Hospital, Green Bay, Wisconsin

Gundersen Lutheran Medical Center, La Crosse, Wisconsin

University of Wisconsin Hospital and Clinics, Madison, Wisconsin

Marshfield Clinic, Marshfield, Wisconsin

Midwest Children's Cancer Center, Milwaukee, Wisconsin

Sydney Children's Hospital, Randwick, New South Wales

Children's Hospital at Westmead, Westmead, New South Wales

Royal Children's Hospital, Brisbane, Queensland

Women's and Children's Hospital, North Adelaide, South Australia

Royal Children's Hospital, Parkville, Victoria

Princess Margaret Hospital for Children, Perth, Western Australia

Alberta Children's Hospital, Calgary, Alberta

Cross Cancer Institute, Edmonton, Alberta

British Columbia Children's Hospital, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador

IWK Health Centre, Halifax, Nova Scotia

Children's Hospital, Hamilton, Ontario

Children's Hospital of Western Ontario, London, Ontario

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital for Sick Children, Toronto, Ontario

McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec

Hopital Sainte Justine, Montreal, Quebec

Centre Hospitalier de L'Universite Laval, Sainte Foy, Quebec

Laval University Medical Center, Sainte-Foy, Quebec

Allan Blair Cancer Centre, Regina, Saskatchewan

Saskatoon Cancer Centre, Saskatoon, Saskatchewan

Academisch Ziekenhuis Groningen, Groningen, Not set

Starship Children's Hospital, Auckland, Not set

University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Not set

San Jorge Childrens Hospital, Santurce, Not set

Swiss Pediatric Oncology Group Bern, Bern, Not set

Swiss Pediatric Oncology Group Geneva, Geneva, Not set

Swiss Pediatric Oncology Group Lausanne, Lausanne, Not set

Conditions: Kidney Cancer

Learn More ›

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

NCT00439296

Terminated

This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemot... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

02/22/2021

Locations: Childrens Hospital Los Angeles, Los Angeles, California +4 locations

Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL

Learn More ›

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

NCT02981524

Completed

This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

02/08/2021

Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Conditions: Metastatic Colorectal Cancer

Learn More ›

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004031

Completed

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation and kill more cancer cells. It is not yet known whether chemoradiotherapy plus peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating non-Hodgkin's lymphoma... Read More

Gender:

ALL

Ages:

Between 15 years and 65 years

Trial Updated:

01/29/2021

Locations: Oregon Health & Science University, Portland, Oregon +14 locations

Conditions: Lymphoma

Learn More ›

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00470301

Completed

Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib together with combination chemotherapy may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2021

Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +6 locations

Conditions: Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer

Learn More ›

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

NCT04536922

Withdrawn

Background: A cancer treatment has been developed called "gene transfer" or "gene therapy." It involves taking white blood cells from a person (called apheresis), genetically modifying the cells in a lab to recognize cancer, and then giving the cells back to the person. Researchers want to see if this treatment can help people with metastatic squamous cell anal cancer. Objective: To see if treating cancer with a person s own white blood cells that have been genetically modified can cause tumo... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

01/29/2021

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic HPV-16 Positive Squamous Cell Anal Cancer

Learn More ›